New tools for functional mammalian cancer genetics
Open accessThe DOI matches its Crossref record; 73 of the 75 references it cites were found in a registry or an index.
Abstract
Knowledge of the function of individual genes that encode components of cell-signalling pathways is crucial to our understanding of normal growth control and its deregulation in cancer, but we have functional information for only 15% of human genes at present. Several new technologies have recently become available to identify gene function in mammalian cells using high-throughput genetic screens. These new tools will make it possible to identify new and innovative classes of anticancer drugs, including those that show synthetic lethal interactions with cancer-specific mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Almost all of the immortal cell clones that emerge have defects in either p53 or one of its upstream regulators or downstream effectors (16,17)”
From Glycolytic Enzymes Can Modulate Cellular Life Span (2005) · cites this paper as [16]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“The discovery of a cellular response against double-stranded RNA 37 , however, has provided one of the most powerful tools to turn off gene expression, and this has revolutionized loss-of-function genetics, initially in C. elegans and Drosophila and also more recently in mammalian cells.”
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456 · cited 1×
“…(for example , a yeast two-hybrid screen) is required to identify the cellular protein that is affected by the interaction with the selected short peptide. short RNAs can recruit mammalian RISC to target mRNAs and induce their specific degradation, but do not activate the γ -interferon pathway 45 .”
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451 · cited 2×
“The discovery of methods to introduce foreign DNA into mammalian cells, now some 30 years ago, provided the first powerful tools to study gene function on a large scale 4 .”
Functional profiling of the Saccharomyces cerevisiae genome
Giaever, G., Chu, A. M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., André, B., et al. (2002) · Nature · doi:10.1038/nature00935 · Cited by 4,316 · cited 1×
“Molecular barcodes were first used in yeast genetic screens, in which large numbers of yeast genes were inactivated by insertion of a DNA segment that contained a unique 20-nucleotide sequence (the 'molecular barcode') to mark the individual knockout yeast strain”
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291 · cited 1×
“Several groups have effectively resolved these issues through the development of vector systems that mediate stable production of siRNA-like molecules in mammalian cells 46–50 (FIG.”
Self-citationFunctional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis
Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J. D., Bussey, H., et al. (1999) · Science · doi:10.1126/science.285.5429.901 · Cited by 3,953 · cited 1×
“Molecular barcodes were first used in yeast genetic screens, in which large numbers of yeast genes were inactivated by insertion of a DNA segment that contained a unique 20-nucleotide sequence (the 'molecular barcode') to mark the individual knockout yeast strain”
Systematic functional analysis of the Caenorhabditis elegans genome using RNAi
Kamath, R. S., Fraser, A. G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., Le Bot, N., Moreno, S., Sohrmann, M., et al. (2003) · Nature · doi:10.1038/nature01278 · Cited by 3,616 · cited 1×
“Such large-scale genetic loss-of-function screens have allowed the identification of genes that affect worm development 40,41 , regulate fat storage 42 or serve to protect the genome against mutations 43 .”
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 1×
“Some ‘off-target’side effects have been reported 60–62 , which in most cases can be attributed to partial homology of the un-intended target to the siRNA.”
Cited by
A General Framework for Weighted Gene Co-Expression Network Analysis
Zhang, B., & Horvath, S. (2005) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1128 · Cited by 5,684
“This facilitates novel strategies for screening for therapeutic targets (Brummelkamp and Bernards, 2003; Sonoda, 2003; Carter et al. , 2004; Mischel et al. , 2005).”
A large-scale RNAi screen in human cells identifies new components of the p53 pathway
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature · doi:10.1038/nature02371 · Cited by 1,065
Self-citationReversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Self-citationGlycolytic Enzymes Can Modulate Cellular Life Span
Kondoh, H., Lleonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., & Beach, D. (2005) · Cancer Research · doi:10.1158/0008-5472.177.65.1 · Cited by 647
“one of its upstream regulators or downstream effectors (16, 17), in line with a direct involvement of p53 in the response to oxidative stress (18).”
BackgroundThe Fanconi Anemia/BRCA pathway: new faces in the crowd
Kennedy, R. D., & D'Andrea, A. D. (2005) · Genes & Development · doi:10.1101/gad.1370505 · Cited by 467
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Genome-scale loss-of-function screening with a lentiviral RNAi library
Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S., & Sabatini, D. M. (2006) · Nature Methods · doi:10.1038/nmeth924 · Cited by 357
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Improving the efficiency of RNA interference in mammals
Mittal, V. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1323 · Cited by 286
van Noort, V., Snel, B., & Huynen, M. A. (2004) · EMBO reports · doi:10.1038/sj.embor.7400090 · Cited by 256
“The structure of the resulting interaction networks is relevant to the functioning of the cell, for example, in development (Davidson et al, 2003), and for the interpretation of experimental results.”
BackgroundA library of gene expression signatures to illuminate normal and pathological lymphoid biology
Shaffer, A. L., Wright, G., Yang, L., Powell, J., Ngo, V., Lamy, L., Lam, L. T., Davis, R. E., & Staudt, L. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00373.x · Cited by 228
Genome‐wide screening for gene function using RNAi in mammalian cells
Cullen, L. M., & Arndt, G. M. (2005) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2005.01332.x · Cited by 214
Molecular mechanisms of natural killer cell activation in response to cellular stress
Chan, C. J., Smyth, M. J., & Martinet, L. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.26 · Cited by 213
Building mammalian signalling pathways with RNAi screens
Moffat, J., & Sabatini, D. M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1860 · Cited by 202
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 189
Self-citationShort interfering RNAs as a tool for cancer gene therapy
Izquierdo, M. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700791 · Cited by 190
Mammalian RNAi: a Practical Guide
Sandy, P., Ventura, A., & Jacks, T. (2005) · BioTechniques · doi:10.2144/05392rv01 · Cited by 149
shRNA libraries and their use in cancer genetics
Bernards, R., Brummelkamp, T. R., & Beijersbergen, R. L. (2006) · Nature Methods · doi:10.1038/nmeth921 · Cited by 159
Self-citationTian, S., Roepman, P., Veer, L. J. V., Bernards, R., Snoo, F. D., & Glas, A. M. (2010) · Biomarker Insights · doi:10.4137/bmi.s6184 · Cited by 155
Self-citationGodinho, M., Meijer, D., Setyono-Han, B., Dorssers, L. C. J., & van Agthoven, T. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22503 · Cited by 119
“Therefore, in subsequent screens, we applyed a retroviral transduction-based approach utilizing cDNA expression libraries (Brummelkamp and Bernards, 2003).”
MethodMicroarrays of lentiviruses for gene function screens in immortalized and primary cells
Bailey, S. N., Ali, S. M., Carpenter, A. E., Higgins, C. O., & Sabatini, D. M. (2006) · Nature Methods · doi:10.1038/nmeth848 · Cited by 130
Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells
Meijer, D., van Agthoven, T., Bosma, P. T., Nooter, K., & Dorssers, L. C. J. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0156 · Cited by 117
“In this study, we used replication-defective retroviruses to express cDNAs, a strategy that has previously been used for various experimental purposes (8-10).”
MethodRottmann, S., Wang, Y., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505114102 · Cited by 107
Large-scale cDNA transfection screening for genes related to cancer development and progression
Wan, D., Gong, Y., Qin, W., Zhang, P., Li, J., Wei, L., Zhou, X., Li, H., Qiu, X., Zhong, F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404089101 · Cited by 100
Towards systematic functional characterization of cancer genomes
Boehm, J. S., & Hahn, W. C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3013 · Cited by 90
Chemical Genetics: Drug Screens in Zebrafish
den Hertog, J. (2005) · Bioscience Reports · doi:10.1007/s10540-005-2891-8 · Cited by 88
“Double-stranded RNA-mediated RNA interference has been used to knock down target protein expression in many experimental systems (Hannon, 2002; Brummelkamp and Bernards, 2003).”
Baldwin, A. E., Grueneberg, D. A., Hellner, K., Sawyer, J., Grace, M. R., Li, W., Harlow, E., & Münger, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007462107 · Cited by 85
Viswanatha, R., Li, Z., Hu, Y., & Perrimon, N. (2018) · eLife · doi:10.7554/elife.36333 · Cited by 79
Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
Mullenders, J., & Bernards, R. (2009) · Oncogene · doi:10.1038/onc.2009.295 · Cited by 81
Self-citationFunctional Genomics for Cancer Drug Target Discovery
Haley, B., & Roudnicky, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.006 · Cited by 79
Vanderwaeren, L., Dok, R., Voordeckers, K., Nuyts, S., & Verstrepen, K. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911665 · Cited by 101
“Several of the experimental procedures that were first developed in yeast cells, including barcoded siRNA screens [19,20] or CRISPR screens [21,22] were later also established in mammalian cells.”
BackgroundBcl-2 is a critical mediator of intestinal transformation
van der Heijden, M., Zimberlin, C. D., Nicholson, A. M., Colak, S., Kemp, R., Meijer, S. L., Medema, J. P., Greten, F. R., Jansen, M., Winton, D. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10916 · Cited by 71
Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation
Gao, H., Chakraborty, G., Lee-Lim, A. P., Mavrakis, K. J., Wendel, H., & Giancotti, F. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403234111 · Cited by 69
“Functional genetic screens can lead to the rapid identification of strong mediators of a selectable phenotype (9, 10).”
BackgroundPDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer
Liu, S., Ballian, N., Belaguli, N. S., Patel, S. G., Li, M., Templeton, N. S., Gingras, M., Gibbs, R. A., Fisher, W. P., & Brunicardi, F. C. (2008) · Pancreas · doi:10.1097/mpa.0b013e31816a4a33 · Cited by 70
Sawyer, T. K. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.1 · Cited by 69
Carette, J. E., Overmeer, R. M., Schagen, F. H. E., Alemany, R., Barski, O. A., Gerritsen, W. R., & van Beusechem, V. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3530 · Cited by 60
Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells
Downward, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208073 · Cited by 57
“This strategy, termed ‘barcode’ screening (Brummelkamp and Bernards, 2003; Berns et al., 2004; Paddison et al., 2004), makes use of a gene-specific sequence incorporated into each shRNA vector in the library.”
BackgroundPI3KC2α, a class II PI3K, is required for dynamin-independent internalization pathways
Krag, C., Malmberg, E. K., & Salcini, A. E. (2010) · Journal of Cell Science · doi:10.1242/jcs.071712 · Cited by 47
“…screen and survival assay PI3KC2a was identified as a hit in a screen using a library of shRNA, kindly provided by the NKI Institute, The Netherlands, targeting more than 8000 human genes (a list of target genes is available at http://www.screeninc.nl) (Brummelkamp and Bernards, 2003).”
MethodOptimizing RNA interference for application in mammalian cells
Medema, R. H. (2004) · Biochemical Journal · doi:10.1042/bj20040260 · Cited by 52
The full-ORF clone resource of the German cDNA Consortium
Bechtel, S., Rosenfelder, H., Duda, A., Schmidt, C., Ernst, U., Wellenreuther, R., Mehrle, A., Schuster, C., Bahr, A., Blöcker, H., et al. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-399 · Cited by 47
“To this end, RNA interference (RNAi) has received much attention as a powerful tool for systematic loss-of-function genetic studies on a large scale [7-9].”
BackgroundWu, H. D., Maurer, M. S., Friedman, R. A., Marboe, C. C., Ruiz-Vazquez, E. M., Ramakrishnan, R., Schwartz, A. J., Tilson, M. D., Stewart, A. S., & WINCHESTER, R. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5329 · Cited by 49
Know-how of RNA interference and its applications in research and therapy
Wadhwa, R., Kaul, S. C., Miyagishi, M., & Taira, K. (2004) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2004.06.002 · Cited by 55
Storm, P., Aits, S., Puthia, M., Urbano, A., Northen, T. R., Powers, S., Bowen, B. P., Chao, Y., Reindl, W., Lee, D. Y., et al. (2011) · Oncogene · doi:10.1038/onc.2011.196 · Cited by 43
“An shRNA screen identifies c-Myc and glycolytic-related proteins as modifiers of HAMLET sensitivity To get an unbiased overview of genes important for HAMLET sensitivity, we used the RNA interference barcode screening technology (Brummelkamp and Bernards, 2003; Silva et al., 2005, 2008).”
MethodpHUSH: a single vector system for conditional gene expression
Gray, D. C., Hoeflich, K. P., Peng, L., Gu, Z., Gogineni, A., Murray, L. J., Eby, M., Kljavin, N., Seshagiri, S., Cole, M. J., et al. (2007) · BMC Biotechnology · doi:10.1186/1472-6750-7-61 · Cited by 41
Synthetic Lethal Vulnerabilities of Cancer
de la Cruz, F. F., Gapp, B. V., & Nijman, S. M. B. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124511 · Cited by 51
The Application of siRNA Technology to Cancer Biology Discovery
Fuchs, U., & Borkhardt, A. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)96004-7 · Cited by 40
Dissecting Cancer Pathways and Vulnerabilities with RNAiPreprint
Westbrook, T. F., Stegmeier, F. P., & Elledge, S. J. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.031 · Cited by 34
“The discovery of RNA interference (RNAi) and the subsequent exploitation of this biological phenomenon as a means to manipulate gene expression have begun to revolutionize mammalian genetics (Paddison and Hannon 2002; Brummelkamp and Bernards 2003; Hannon and Rossi 2004).”
BackgroundMethodExpression of WSX1 in Tumors Sensitizes IL-27 Signaling-Independent Natural Killer Cell Surveillance
Dibra, D., Cutrera, J. J., Xia, X., Birkenbach, M. P., & Li, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4311 · Cited by 33
van Agthoven, T., Sieuwerts, A. M., Meijer, D., Gelder, M. E. M., AGTHOVEN, T. L. A. V., Sarwari, R., Sleijfer, S., Foekens, J. A., & Dorssers, L. C. J. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0062 · Cited by 35
WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
Ertay, A., Liu, H., Liu, D., Peng, P., Hill, C. N., Xiong, H., Hancock, D. C., Yuan, X., Przewloka, M. R., Coldwell, M. J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03210-5 · Cited by 55
Navigating the pathway from embryonic stem cells to beta cells
Stoffel, M., Vallier, L., & Pedersen, R. A. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.02.002 · Cited by 39
Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
Tang, L., Chen, R., & Xu, X. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.016 · Cited by 30
Synthetic lethal approaches to target cancers with loss of PTEN function
Ertay, A., Ewing, R. M., & Wang, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.12.015 · Cited by 30
“To identify novel targeted therapies, synthetic lethality screens can be performed, including RNA interference (RNAi) screens.(142,147) One of the well-known examples of synthetic lethality interaction is that between BRCA1/2 and PARP1.”
Understanding transformation: progress and gaps
Boehm, J. S., & Hahn, W. C. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.11.003 · Cited by 37
Lehner, B., Fraser, A. G., & Sanderson, C. M. (2004) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/3.1.68 · Cited by 32
Application of RNAi to cancer research and therapy
Fischer, L. T. (2005) · Frontiers in bioscience · doi:10.2741/1670 · Cited by 28
“Researchers worldwide have used RNAi for functional analysis and target validation (15-16,25,29).”
BackgroundMethodDendritic Cells and Natural Killer Cells in the Pathogenesis of HIV Infection
Fortis, C., & Poli, G. (2005) · Immunologic Research · doi:10.1385/ir:33:1:001 · Cited by 28
Selected technologies to control genes and their products for experimental and clinical purposes
Alexander, H. K., Booy, E. P., Xiao, W., Ezzati, P., Baust, H., & Łoś, M. (2007) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-007-0025-7 · Cited by 31
Hale, K. J., Domostoj, M. M., El‐Tanani, M., Campbell, F. C., & Mason, C. K. (2005) · Strategies and tactics in organic synthesis · doi:10.1016/s1874-6004(05)80034-6 · Cited by 23
Bogliolo, M., & Surrallés, J. (2006) · Springer eBooks · doi:10.1007/0-387-36802-7_6 · Cited by 22
Pooled RNAi Screens - Technical and Biological Aspects
Boettcher, M., & Hoheisel, J. D. (2010) · Current Genomics · doi:10.2174/138920210791110988 · Cited by 20
“introduced a concept termed ‘siRNA bar-code screen’ [28] similar to pioneering studies in yeast [29, 30].”
In vivo CRISPR activation screen identifies acyl-CoA–binding protein as a driver of bone metastasis
Teng, H., Hang, Q., Zheng, C., Yan, Y., Liu, S., Zhao, Y., Deng, Y., Nie, L., Wu, W.-C., Sheldon, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado7225 · Cited by 23
Natural killer cells: versatile roles in autoimmune and infectious diseases
Aktas, E., Erten, G., Küçüksezer, U. C., & Deniz, G. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.27 · Cited by 17
RNA Interference Libraries Prove Their Worth in Hunt for Tumor Suppressor Genes
Downward, J. (2005) · Cell · doi:10.1016/j.cell.2005.06.002 · Cited by 17
“In addition, Westbrook et al. (2005) also used a second approach to identify the genes knocked down: “barcode” screening (Brummelkamp and Bernards, 2003).”
MethodBrummelkamp, T. R., Berns, K., Hijmans, E. M., Mullenders, J., Fabius, A. W. M., Heimerikx, M., Velds, A., Kerkhoven, R. M., Madiredjo, M., Bernards, R., et al. (2004) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2004.69.439 · Cited by 19
“In addition, we describe here the validation of a second way to screen shRNA vector libraries, which we have named “siRNA bar code screening” (Brummelkamp and Bernards 2003).”
MethodSelf-citationFormstecher, É., Reverdy, C., Cholay, M., Planquette, C., Trouplin, V., Lehrmann, H., Aresta, S., Calabrese, A., Arar, K., Daviet, L., et al. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.387 · Cited by 16
“…been successfully conducted in mammalian cells and led to the identification of genes involved in several signaling pathways and regulation of proteasome function (Aza-Blanc et al., 2003; Berns et al., 2004; Brummelkamp et al., 2003; Colland et al., 2004; Paddison et al., 2004; Zheng et al., 2004).”
Functional genomics for breast cancer drug target discovery
Yoshimaru, T., Nakamura, Y., & Katagiri, T. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00962-6 · Cited by 15
Yang, J., Fan, W., Rogers, C., Chatterton, J. E., Bliesath, J. R., Liu, G., Ning, K., Wang, C., Rhoades, K. L., Wong‐Staal, F., et al. (2006) · Genomics · doi:10.1016/j.ygeno.2006.03.010 · Cited by 14
“In the second case, RNAi library vectors are constructed either by PCR [4] or by cloning (plasmid vectors and viral vectors) [1,2,8].”
BackgroundGeneration of RNAi Libraries for High‐Throughput Screens
Clark, J., & Ding, S. (2006) · BioMed Research International · doi:10.1155/jbb/2006/45716 · Cited by 15
“Termed “barcode” screening [46–48], this identification sequence can be located within the vector backbone [48] or function as the short hairpin sequence of the shRNA molecule [46].”
BackgroundTwo decades of PARP inhibitor synthetic lethality in cancer
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2026) · Nature · doi:10.1038/s41586-026-10404-y · Cited by 19
An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression
Edel, M. J., Shvarts, A., Medema, J. P., & Bernards, R. (2004) · Oncogene · doi:10.1038/sj.onc.1207667 · Cited by 10
“Such ‘gain-of-function’ genetic screens are powerful tools to place genes functionally into cancer-relevant pathways (see Brummelkamp and Bernards, 2003 for a review).”
BackgroundSelf-citationFrom RNAi to Epigenomes: How RNA Rules The World
Westhof, É., & Filipowicz, W. (2005) · ChemBioChem · doi:10.1002/cbic.200400418 · Cited by 10
The Role of Drug-Metabolizing Enzymes in Synthetic Lethality of Cancer
Zeng, Z., Zheng, W., & Hou, P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108219 · Cited by 8
Recent development of RNAi in drug target discovery and validation
Liu, G., Wong‐Staal, F., & Li, Q. (2006) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2006.09.003 · Cited by 8
Designer siRNAs to overcome the challenges from the RNAi pathway.
Jayasena, S. D. (2005) · PubMed Central · Cited by 8
RNA interference screening to detect targetable molecules in hematopoietic stem cells
Karlsson, C., Rak, J. M., & Larsson, J. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000053 · Cited by 6
Singleton, K. R., & Wood, K. C. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.112 · Cited by 8
“For example, numerous published screens have identified genes whose loss impairs tumor progression, cell cycle control, growth factor signaling, and migration and invasion [10-17].”
BackgroundHagen, G., Peel, B. J., Samis, J. A., & Desaulniers, J. (2015) · MedChemComm · doi:10.1039/c5md00147a · Cited by 6
Einav, Y., Agami, R., & Canaani, D. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.11.075 · Cited by 6
Molecular Determinants of Chemotherapy Resistance in Ovarian Cancer
Cooley, M., Fang, P., Fang, F., Nephew, K. P., & CHIEN, J. R. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.130 · Cited by 5
Muellner, M. K., Duernberger, G., Ganglberger, F., Kerzendorfer, C., Uras, I. Z., Schönegger, A., Bagienski, K., Colinge, J., & Nijman, S. M. B. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-98 · Cited by 5
“Barcodes can be encoded by short hairpin (sh)RNA sequences themselves or introduced into the genome as non-transcribed DNA sequences using lentiviral vectors [7,8].”
BackgroundCENPV Is a CYLD-Interacting Molecule Regulating Ciliary Acetylated α-Tubulin
Chiticariu, E., Regamey, A., Huber, M., & Hohl, D. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.04.028 · Cited by 6
Exploiting Cancer Synthetic Lethality in Cancer—Lessons Learnt from PARP Inhibitors
Pettitt, S. J., Ryan, C. J., & Lord, C. J. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_2 · Cited by 7
Functional screening revisited in the postgenomic era
Tochitani, S., & Hayashizaki, Y. (2007) · Molecular BioSystems · doi:10.1039/b614882b · Cited by 4
Functional interrogation of breast cancer: from models to drugs
McGee, S. F., O’Connor, D. P., & Gallagher, W. M. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/174604441.1.6.569 · Cited by 5
“When cells are infected with these viral particles, the transgene encoding the desired RNA duplex is incorporated into the host genome to yield stable, sustained expression [54].”
BackgroundInfluentialA functional approach to questions about life, death, and phosphorylation
Bernards, R. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.020 · Cited by 4
Self-citationRehberger, M., Schäfer, J. A., Krampitz, A.-M., Bretz, A. C., Jost, L., Haferlach, T., Stiewe, T., & Neubauer, A. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000708 · Cited by 3
Rehberger, M., Schäfer, J., Krampitz, A.-M., Bretz, A. C., Jost, L., Haferlach, T., Stiewe, T., & Neubauer, A. (2022) · open_UMR Marburg DSpace 10.0 (Philipps-Universität Marburg) · doi:10.17192/es.2022.0171 · Cited by 2
He, F., Ma, Q., & Zhang, J. (2009) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2009.00041 · Cited by 3
Vanet, A., Bazin, C., Coupaye, R., & Middendorp, S. (2014) · Science Postprint · doi:10.14340/spp.2014.10r0002 · Cited by 3
Finding biomarkers of resistance to targeted cancer therapies
Bernards, R. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70031-9 · Cited by 2
Self-citationSystems Biology Approaches to TGF-β/Smad Signaling
Tewari, M., & Rao, A. U. K. (2007) · Springer eBooks · doi:10.1007/1-4020-4709-6_18 · Cited by 1
CHIEN, J. R. (2013) · Journal of Cancer Biology & Research · Cited by 1
Aliu, H., Beadini, N., Beadini, S., & Iseni, G. (2013) · Cited by 1
Next-Generation Sequencing for High-Throughput RNA Interference Screens
Ward, T. M., Jegg, A.-M., & Iorns, E. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7645-0_14 · Cited by 2
An in vivo functional genetic screen for suppressors of the Rag1−/− T-cell defect
Chan, A. C., Smeets, M. F. M. A., & Izon, D. J. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.07.017 · Cited by 1
Genome-Wide RNA Interference Screening
Goodall, M. L., & MacKeigan, J. P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00016-1 · Cited by 1
INTEGRATIVE BIOINFORMATICS OF FUNCTIONAL AND GENOMIC PROFILES FOR CANCER SYSTEMS MEDICINE
Jaiswal, A. (2018) · Helda - University of Helsinki Institutional Repository · Cited by 2
Genome Scanning by RNA Interference
Beijersbergen, R. L., & Steinbach, O. C. (2010) · Wiley eBooks · doi:10.1002/9780470923733.ch4
Identifying Genes Responsible for Tamoxifen Resistance in Breast Cancer
Meijer, D. (2008) · RePub (Erasmus University Rotterdam)
Metadata
- Authors
- Brummelkamp, T. R., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Bernards, René
- Venue
- Nature Reviews Cancer
- Published
- 2003-12
- Volume
- 3
- Issue
- 10
- Pages
- 781-789
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2165874246
- Cited by
- 114
- References
- 75
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 3 · 2016: 2 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 2
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Funders
- KWF Kankerbestrijding
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- cancer genetics, gene function, cell signalling pathways, high-throughput genetic screens, anticancer drug discovery, synthetic lethality, tumor-specific mutations, mammalian cells
- MeSH terms
- Animals, Genetic Techniques, Humans, Mammals, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.